Abstract
The presence of a third β-adrenergic receptor (β3-AR) in the cardiovascular system has challenged the classical paradigm of sympathetic regulation by β1- and β2-adrenergic receptors. While β3-AR's role in the cardiovascular system remains controversial, increasing evidence suggests that it serves as a "brake" in sympathetic overstimulation - it is activated at high catecholamine concentrations, producing a negative inotropic effect that antagonizes β1- and β2-AR activity. The anti-adrenergic effects induced by β3-AR were initially linked to nitric oxide (NO) release via endothelial NO synthase (eNOS), although more recently it has been shown under some conditions to increase NO production in the cardiovascular system via the other two NOS isoforms, namely inducible NOS (iNOS) and neuronal NOS (nNOS). We summarize recent findings regarding β3-AR effects on the cardiovascular system and explore its prospective as a therapeutic target, particularly focusing on its emerging role as an important mediator of NO signaling in the pathogenesis of cardiovascular disorders.
Original language | English (US) |
---|---|
Pages (from-to) | 1088-1095 |
Number of pages | 8 |
Journal | Journal of Molecular and Cellular Cardiology |
Volume | 48 |
Issue number | 6 |
DOIs | |
State | Published - Jun 2010 |
Keywords
- Beta 3 adrenergic receptor
- Cardiovascular
- Heart failure
- Nitric oxide synthase
ASJC Scopus subject areas
- Molecular Biology
- Cardiology and Cardiovascular Medicine